600351.SH
亚宝药业
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 6.78
−1.31%Year over year
Reported trailing growth
- Revenue
- -13.1%
- EBITDA
- —
- EBIT
- +25.9%
- EPS
- +38.1%
- Free cash flow
- +93.0%
- Operating cash flow
- +82.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -6.2%
- EBITDA
- +21.2%
- EBIT
- +44.3%
- Net income
- +45.1%
- EPS
- +48.7%
- Free cash flow
- +9.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026